AMRI has signed a definitive agreement to acquire Oso Biopharmaceuticals Manufacturing, LLC for $110 million in cash. OsoBio is a contract manufacturer of highly complex injectable drug products, including sterile liquid, suspension and lyophilized formulations. The acquisition, subject to customary closing conditions, is expected to close in 3Q14.   Based in Albuquerque, NM, OsoBio’s core capabilities include liquid fill and lyophilized products, highly potent compounds, cytotoxics, prote...